Replies to post #394542 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Recent GBM definition change that correlates with DCVax-l’s perceived MOA.
Manufacturing almost certified (Expected by Sept 30), in Sawston, to handle more capacity than CU in UK.
GBM definition change will otherwise leave a void for first line treatment against GBM.
Results are one, two and three priority at NWBO.
CRL owns Cognate, Cognate already certified.
CRL is present and doing business in all ORBIS countries.
GBM diagnosis is increasing around the world.
World Health Organization Blue Book will formally cement GBM definition change later this summer.
EANO and SNO already recognize the definitional change.
Current Standard of care only provides median survival of 15 months under new definition of GBM.